title: [Anemia of prematurity and treatment with recombinant human erythropoietin (rHuEPO): is there a benefit?].
authors.forename: S
authors.initials: S
authors.lastname: Klosowski
authors.forename: A
authors.initials: A
authors.lastname: Djebara
authors.forename: A
authors.initials: A
authors.lastname: Bachiri
authors.forename: N
authors.initials: N
authors.lastname: Haouari
authors.forename: P
authors.initials: P
authors.lastname: Thelliez
authors.forename: C
authors.initials: C
authors.lastname: Morisot
mesh_terms: D000751:Anemia, Neonatal / Q000188:drug therapy*; D004921:Erythropoietin / Q000627:therapeutic use*; D005296:Ferrous Compounds / Q000627:therapeutic use; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D011994:Recombinant Proteins; D016896:Treatment Outcome
chemical_list: D005296:Ferrous Compounds; D011994:Recombinant Proteins; D004921:Erythropoietin; C031621:ferrous fumarate